Page last updated: 2024-11-03
propidium and Devic Disease
propidium has been researched along with Devic Disease in 1 studies
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Neuromyelitis optica is an inflammatory demyelinating central nervous system disease, usually relapsing, that causes variable degrees of attack-related disability." | 1.35 | Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. ( Apiwattanakul, M; Fryer, JP; Hinson, SR; Lennon, VA; McKeon, A; Pittock, SJ, 2009) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Hinson, SR | 1 |
| McKeon, A | 1 |
| Fryer, JP | 1 |
| Apiwattanakul, M | 1 |
| Lennon, VA | 1 |
| Pittock, SJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica[NCT00904826] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2009-04-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Expanded Disability Status Scale (EDDS) Score
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments. (NCT00904826)
Timeframe: baseline, 12 months
| Intervention | units on a scale (Mean) |
|---|
| Eculizumab | -0.7 |
Mean Eculizumab Concentration in Cerebrospinal Fluid (CSF)
(NCT00904826)
Timeframe: 3 months
| Intervention | ng/mL (Mean) |
|---|
| Eculizumab | 34.7 |
Number of Subjects With Change in Ambulation by at Least 1 Point
Ambulation was measured by the Hauser Ambulation Index, which ranges from 0 (asymptomatic; fully active) to 9 (restricted to wheelchair; unable to transfer self independently.) (NCT00904826)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|
| Eculizumab | 3 |
Number of Subjects With Change in Visual Acuity in at Least One Eye by at Least One Point
Visual acuity was measured using the the Visual Acuity subscale of the Opticospinal Impairment Score (OSIS) for Exacerbations. This subscale ranges from 0 (normal) to 8 (no light perception). (NCT00904826)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|
| Eculizumab | 5 |
Number Subjects Experiencing an NMO Attack in 12 Months of Eculizumab Treatment
(NCT00904826)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|
| Eculizumab | 2 |
Mean Complement Protein 5 (C5) Concentration in CSF
(NCT00904826)
Timeframe: baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|
| Baseline | 3 months |
|---|
| Eculizumab | 144 | 60.8 |
Mean Serum Concentration of Eculizumab
(NCT00904826)
Timeframe: 6 weeks, 3 months, 6 months, 9 months, 12 months
| Intervention | micrograms/mL (Mean) |
|---|
| 6 weeks | 3 months | 9 months | 12 months |
|---|
| Eculizumab | 206 | 187 | 230 | 246 |
Median Number of Neuromyelitis Optica (NMO) Attacks Per Year
(NCT00904826)
Timeframe: baseline, after 12 months of treatment
| Intervention | attacks per year (Median) |
|---|
| Baseline | After 12 months of treatment |
|---|
| Eculizumab | 3 | 0 |
Percentage Hemolysis
Percentage of hemolysis is a measure of complement activity. Less than 20% lysis is deemed to be complete complement inhibition. (NCT00904826)
Timeframe: baseline, 6 weeks, 3 months, 6 months, 9 months, 12 months
| Intervention | percentage of hemolysis (Mean) |
|---|
| Baseline | 6 weeks | 3 months | 6 months | 9 months | 12 months |
|---|
| Eculizumab | 88.5 | 0.4 | 0 | 0.2 | 0.4 | 0.9 |
Other Studies
1 other study available for propidium and Devic Disease